L&C Bio reports third-quarter operating profit up 239.7% to 9.8 billion won
L&C Bio disclosed preliminary consolidated third-quarter operating profit of 9.8 billion won, up 239.7% year on year. Revenue rose 70.5% to 38.4 billion won, while net profit reached 4.9 billion won, returning to profitability. Revenue for the first nine months increased 76.8% to 107.5 billion won, exceeding 100 billion won for the first time. The company attributed growth to expanded domestic medical-institution supply of its ECM-based product and steady growth in its existing human tissue-graft business.